Norbert Prenzel
Norbert Prenzel is an experienced business and corporate development expert with more than 20 years track record of licensing and M&A in Biotech and Pharma. Dr. Prenzel earned his PhD summa cum laude in Axel Ullrich’s department at the Max Planck Institute for Biochemistry in Martinsried and holds an Executive MBA from the WHU/Kellogg School of Management. His doctoral work on signal transduction and cancer was recognized with the Max Planck Society’s Junior Research Award.
Before joining SOTIO, Norbert was co-founder of U3 Pharma AG (acquired by Daiichi Sankyo), business development consultant at Staatz Business Development & Strategy, Director of Business Development at Micromet Inc. (acquired by Amgen) and he served as Licensing Director at Amgen Inc.
Norbert joined SOTIO in 2015 as Head of Business Development and Licensing where he leads global partnering and fundraising efforts across the company’s innovative oncology portfolio.
SOTIO Biotech B.V.
Zuidplein 168
1077 XV Amsterdam
Netherlands
Zuidplein 168
1077 XV Amsterdam
Netherlands
SOTIO Biotech a.s.
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
SOTIO Biotech AG
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
SOTIO Biotech Inc.
180 Canal St., Suite 300
Boston, MA 02114
USA
180 Canal St., Suite 300
Boston, MA 02114
USA
